A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Subjects With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody



Status:Recruiting
Conditions:Blood Cancer, Hematology, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:4/6/2019
Start Date:June 18, 2018
End Date:June 22, 2020
Contact:US GSK Clinical Trials Call Center
Email:GSKClinicalSupportHD@gsk.com
Phone:877-379-3718

Use our guide to learn which trials are right for you!

A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)

Multiple myeloma (MM) is an incurable malignancy and accounts for 1 percentage of all cancers
and for 10% of all hematologic malignancies. Subjects with relapsed/refractory multiple
myeloma (RRMM) will be included in this study, to evaluate the efficacy and safety of
GSK2857916 monotherapy. Subjects will be treated with GSK2857916 monotherapy until disease
progression or unacceptable toxicity and will be followed for Progression Free Survival (PFS)
and Overall survival (OS). The subjects will be randomized to receive either frozen
GSK2857916 at the dose of 2.5 milligram per kilogram (mg/kg) or 3.4 mg/kg Intravenous (IV).
There will be an independent cohort of subjects who will receive a lyophilized configuration
of GSK2857916. Approximately 155 subjects will be enrolled in the study of which 130 subjects
will be enrolled to receive frozen GSK2857916 and 25 subjects will be enrolled in the
independent lyophilized drug product cohort. The subjects who discontinued from the study
other than Progressive disease (PD), disease evaluation will continue to be performed at
3-week intervals until confirmed PD, death, start of a new anticancer treatment, withdrawal
of consent, or end of the study whichever occurs first.


Inclusion Criteria:

- Subjects provide signed written informed consent, which includes compliance with the
requirements and restrictions listed in the consent form.

- Male or female, 18 years or older.

- Subjects with Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

- Histologically or cytologically confirmed diagnosis of MM as defined according to
International Myeloma Working Group (IMWG). The subject has undergone stem cell
transplant or is considered transplant ineligible and has failed at least 3 prior
lines of anti-myeloma treatments, including an anti-CD38 antibody (example [e.g.],
daratumumab) alone or in combination, and is refractory to an Immunomodulatory drugs
(IMiD) (that is [i.e.], lenalidomide or pomalidomide), and to a proteasome inhibitor
(i.e., bortezomib, ixazomib or carfilzomib).

- The subject has measurable disease with at least one of the following: Serum M-protein
>=0.5 gram per deciliter (g/dL) (>=5 gram per Liter [g/L]); Urine M-protein >=200
milligram per 24 hours (mg/24h); Serum Free light chain (FLC) assay: Involved FLC
level >=10 mg/dL (>=100 mg/L) and an abnormal serum free light chain ratio (<0.26 or
>1.65).

- Subjects with a history of autologous stem cell transplant are eligible for study
participation provided the following eligibility criteria are met: transplant was >100
days prior to study enrolment; no active infection(s); subjects meets the remainder of
the eligibility criteria outlined in this protocol.

- Subjects with adequate organ system functions as defined follows: Absolute neutrophil
count (ANC) >=1.0 X 10^9/L; Hemoglobin >=8.0 g/dL; Platelets>= 50 X 10^9/L; Total
bilirubin <=1.5X Upper limit of normal (ULN). Isolated bilirubin >=1.5xULN is
acceptable if bilirubin is fractionated and direct bilirubin <35 percent); Alanine
aminotransferase (ALT) <=2.5X ULN; Estimated glomerular filtration rate (eGFR) >=30
milliliter per minute per 1.73 meter square (mL/min/m^2); Spot urine
(albumin/creatinine ratios [spot urine]) < 500 milligram per gram (mg/g) (56 mg per
millimoles [mg/mmol]); Left ventricular ejection fraction (LVEF) >= 45 percent.

- Female subjects: Contraceptive use by men or women should be consistent with local
regulations regarding the methods of contraception for those participating in clinical
studies. A female subject is eligible to participate if she is not pregnant or
breastfeeding, and not a woman of childbearing potential (WOCBP) or is a WOCBP and
using a contraceptive method that is highly effective (with a failure rate of <1% per
year), preferably with low user dependency, during the intervention period and for at
least 80 days after the last dose of study intervention and agrees not to donate eggs
(ova, oocytes) for the purpose of reproduction during this period. The investigator
should evaluate the effectiveness of the contraceptive method in relationship to the
first dose of study intervention. A WOCBP must have a negative highly sensitive serum
pregnancy test (as required by local regulations) within 72 hours before the first
dose of study intervention.

- Male subjects are eligible to participate if they agree to the following during the
intervention period and for at least 140 days: Refrain from donating sperm; Be
abstinent from heterosexual intercourse as their preferred and usual lifestyle
(abstinent on a long term and persistent basis) and agree to remain abstinent; Agree
to use a male condom and female partner to use an additional highly effective
contraceptive method with a failure rate of <1 percent per year as when having sexual
intercourse with a woman of childbearing potential who is not currently pregnant.

- All prior treatment-related toxicities (defined by National Cancer Institute- Common
Toxicity Criteria for Adverse Events (NCI-CTCAE), version 4.03, must be <=Grade 1 at
the time of enrolment except for alopecia and Grade 2 peripheral neuropathy.

- For France only: A subject will be eligible for inclusion in this study only if either
affiliated to or a beneficiary of a social security category.

Exclusion Criteria:

- Systemic anti-myeloma therapy within <14 days, or plasmapheresis within 7 days prior
to the first dose of study drug.

- Symptomatic amyloidosis, active 'polyneuropathy, organomegaly, endocrinopathy, myeloma
protein, and skin changes' (POEMS) syndrome, active plasma cell leukemia at the time
of screening.

- Prior allogeneic stem cell transplant.

- Current corneal epithelial disease except mild punctate keratopathy.

- Use of an investigational drug within 14 days or five half-lives, whichever is
shorter, preceding the first dose of study drug. Prior treatment with a monoclonal
antibody within 30 days of receiving the first dose of study drugs. Prior BCMA
targeted therapy.

- Evidence of active mucosal or internal bleeding.

- Any major surgery within the last four weeks.

- Presence of active renal condition (infection, requirement for dialysis or any other
condition that could affect subject's safety). Subjects with isolated proteinuria
resulting from MM are eligible.

- Any serious and/or unstable pre-existing medical, psychiatric disorder or other
conditions (including lab abnormalities) that could interfere with participant's
safety, obtaining informed consent or compliance to the study procedures.

- Current unstable liver or biliary disease per investigator assessment defined by the
presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or
gastric varices, persistent jaundice, or cirrhosis. Stable chronic liver disease
(including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement
of malignancy is acceptable if subject otherwise meets entry criteria.

- Malignancies other than disease under study are excluded, except for any other
malignancy from which the subject has been disease-free for more than 2 years and, in
the opinion of the principal investigators and GSK Medical Monitor, will not affect
the evaluation of the effects of this clinical trial treatment on the currently
targeted malignancy (MM).

- Evidence of cardiovascular risk including any of the following: Corrected QT interval
Fridericia (QTcF) interval >=470 milliseconds (msecs); Evidence of current clinically
significant uncontrolled arrhythmias, including clinically significant ECG
abnormalities such as 2nd degree (Type II) or 3rd degree atrioventricular (AV) block;
History of myocardial infarction, acute coronary syndromes (including unstable
angina), coronary angioplasty, or stenting or bypass grafting within six months of
Screening; Class III or IV heart failure as defined by the New York Heart Association
functional classification system (NYHA); Uncontrolled hypertension.

- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
chemically related to GSK2857916, or any of the components of the study treatment.

- Pregnant or lactating female.

- Active infection requiring antibiotic, antiviral, or antifungal treatment.

- Known Human Immunodeficiency Virus (HIV) infection.

- Presence of hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb
at screening or within 3 months prior to first dose of study treatment.

- Positive hepatitis C antibody test result or positive hepatitis C Ribonucleic acid
(RNA) test result at screening or within 3 months prior to first dose of study
treatment. Subjects with positive Hepatitis C antibody due to prior resolved disease
can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained.
We found this trial at
23
sites
Baltimore, Maryland 21201
Principal Investigator: Ashraf Badros
Phone: 877-379-3718
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Atlanta, Georgia 30341
Principal Investigator: Asad Bashey
Phone: 877-379-3718
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Boston, Massachusetts 02115
Principal Investigator: Paul Richardson
Phone: 877-379-3718
?
mi
from
Boston, MA
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
Principal Investigator: Brandi N Reeves
Phone: 877-379-3718
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Charlotte, North Carolina 28203
Principal Investigator: Peter M Voorhees
Phone: 877-379-3718
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Chicago, Illinois 60611
Principal Investigator: Andrzej J Jakubowiak
Phone: 877-379-3718
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Columbus, Ohio 43219
Principal Investigator: Maria Chaudhry
Phone: 877-379-3718
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Dallas, Texas 75230
Principal Investigator: Andrew Whiteley
Phone: 877-379-3718
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Fairway, Kansas 66205
Principal Investigator: Al-Ola Abdallah
Phone: 877-379-3718
?
mi
from
Fairway, KS
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Hans Lee
Phone: 877-379-3718
?
mi
from
Houston, TX
Click here to add this to my saved trials
Indianapolis, Indiana 46202
Principal Investigator: Attaya Suvannasankha
Phone: 877-379-3718
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Madison, Wisconsin 53792
Principal Investigator: Natalie Callander
Phone: 877-379-3718
?
mi
from
Madison, WI
Click here to add this to my saved trials
Middletown, New Jersey 07748
Principal Investigator: Nikoletta Lendvai
Phone: 877-379-3718
?
mi
from
Middletown, NJ
Click here to add this to my saved trials
Montvale, New Jersey 07645
Principal Investigator: Nikoletta Lendvai
Phone: 877-379-3718
?
mi
from
Montvale, NJ
Click here to add this to my saved trials
Nashville, Tennessee 37203
Principal Investigator: Robert Frank Cornell
Phone: 877-379-3718
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New Haven, Connecticut 06520
Principal Investigator: Natalia Neparidze
Phone: 877-379-3718
?
mi
from
New Haven, CT
Click here to add this to my saved trials
New Orleans, Louisiana 70112
Principal Investigator: Laura Finn
Phone: 877-379-3718
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
New York, New York 10032
Principal Investigator: Nikoletta Lendvai
Phone: 877-379-3718
?
mi
from
New York, NY
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Principal Investigator: Adam D Cohen
Phone: 877-379-3718
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Prashant Kapoor
Phone: 877-379-3718
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Salt Lake City, Utah 84132
Principal Investigator: Douglas W Sborov
Phone: 877-379-3718
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Seattle, Washington 98109
Principal Investigator: Edward Libby
Phone: 877-379-3718
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Woodville, South Australia
Principal Investigator: Huey-Shin Cindy Lee
Phone: 877-379-3718
?
mi
from
Woodville,
Click here to add this to my saved trials